PR Newswire Asia's news > Biotechnology

 < Previous page   |   Detail   |   Print    Next page > 
     
Dizal Announces Positive Topline Phase 3 Results from WU-KONG28 Study: Evaluating Oral, Once-Daily ZEGFROVY® (Sunvozertinib) vs. Platinum-Containing Chemo Doublet in First-Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutation (exon20ins)
2026-03-21T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Quality Protein No Longer a Luxury? Angel Yeast Shows How at FIC 2026
2026-03-20T    Beverages   Biotechnology   Computer/Electronics 
Henlius Reports 2025 Results: Sustained Growth in Both Revenue and Profit, Advancing Innovation Validation and Global Operations
2026-03-20T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Earendil Labs Announces $787 Million in Financing to Scale AI-Driven Biologics Discovery and Development
2026-03-20T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Antengene Announces 2025 Full-Year Results: First TCE Out-licensing Validates Platform Value and Marks Inflection Point Towards 2026 Profitability
2026-03-20T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Tescan Opens New Demo Lab in Korea to Support Semiconductor Failure Analysis, Reliability, and Academic Research Across Asia-Pacific
2026-03-20T    Biotechnology   Computer/Electronics   Semiconductors 
Ribo expands beyond the liver with RiboPepSTAR™ - enabling targeted siRNA delivery to multiple organs
2026-03-20T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
MGI Tech and NUS Pharmacy and Pharmaceutical Sciences Announce Collaboration on DCS Lab to Accelerate Multi-Omics Innovation in Pharmaceutical Sciences
2026-03-20T    Biotechnology   Education   Health Care/Hospital   Higher Education 
Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Triple-Negative Breast Cancer of TROP2/HER3 Bispecific ADC JSKN016
2026-03-20T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
D3 Bio to Showcase Its Innovative KRAS Pipeline at AACR 2026, Including an Oral Presentation at Clinical Plenary Session
2026-03-20T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
 < Previous page    Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.